To understand the immunogenicity of Covisheild vaccine in patients with RA by discontinuing methotrexate temporarily
Not Applicable
- Conditions
- Health Condition 1: M061- Adult-onset Stills diseaseHealth Condition 2: M315- Giant cell arteritis with polymyalgia rheumaticaHealth Condition 3: M058- Other rheumatoid arthritis with rheumatoid factorHealth Condition 4: M060- Rheumatoid arthritis without rheumatoid factorHealth Condition 5: M45-M49- SpondylopathiesHealth Condition 6: M30-M36- Systemic connective tissue disorders
- Registration Number
- CTRI/2021/07/034639
- Lead Sponsor
- Centre for Arthritis and Rheumatism Excellence CARE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Inclusion Criteria
Patient above 18 years of age.
Patients willing to give consent for the study
Patients with a prior diagnosis of Autoimmune Rheumatic disease(AIRD)
stable dose for at least the past 2 months
Exclusion Criteria
Exclusion Criteria
Patients who had covid-19 infection in the past.
Patients with history of allergy to vaccine components .
Prior GBS/demyelinating syndromes
Any live vaccine taken within prior 4 weeks or inactivated vaccine in last 2 weeks before study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the anti spike/neutralizing antibody titre and T cell ELIspot assay will be assessed 1 month after the second dose of vaccine and to see if there is statistically significant difference among the two groups studiedTimepoint: 1 month post 2nd dose vaccine
- Secondary Outcome Measures
Name Time Method ilTimepoint: NA